Co-prescribing of topical and systemic beta-blockers in patients with glaucoma: A quality use of medicine issue in Australian practice

Clinical and Experimental Ophthalmology

Volumn 35, Issue 8, 2007, Pages 700-705

  Goldberg, Ivan ^a   Adena, Michael A ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Pty Ltd   (Australia)

Author keywords

Beta blocker; Glaucoma; Side effect

Indexed keywords

ANTIGLAUCOMA AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CARVEDILOL; DORZOLAMIDE PLUS TIMOLOL; LABETALOL; LEVOBUNOLOL; METOPROLOL; OXPRENOLOL; PILOCARPINE; PINDOLOL; PROPRANOLOL; SOTOLOL; TIMOLOL; UNCLASSIFIED DRUG;

AGED; ARTICLE; AUSTRALIA; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; FEMALE; GLAUCOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; QUALITY CONTROL; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AUSTRALIA; DRUG UTILIZATION REVIEW; FEMALE; GLAUCOMA; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PHARMACY; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; QUALITY INDICATORS, HEALTH CARE; RETROSPECTIVE STUDIES; SEX DISTRIBUTION;

EID: 36048995605     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2007.01573.x     Document Type: Article

References (35)

1. Bush JK, Dai WS, Dieck GS et al. The art and science of risk management: a US research-based industry perspective. Drug Safety 2005; 28: 1-18.
2. Food and Drug Administration, Centres for Disease Control and Prevention. Strategic Action Plan Food and Drug Administration. Protecting and Advancing America's Health. 2003. Accessed October 2005. Available at: http://www.fda.gov/oc/mcclellan/strategic.html
3. Heads of Medicines Agencies Management Group. Report of the ad hoc Working Group progress on implementation of the European Risk Management Strategy. 2005. Accessed October 2005. Available at: http://heads.medagencies.org/heads/docs/MMA_2ndreport_20050511.pdf
4. Australian Government, Department of Health and Ageing National Strategy for Quality Use of Medicines. 2002. Accessed October 2005. Available at: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/ nmp-pdf-natstrateng-cnt.htm/$FILE/natstrateng.pdf
5. Diamond JP. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging 1997; 11: 352-60.
6. Rait JL. Management of ocular hypertension and primary open angle glaucoma. Clin Exp Optom 2000; 83: 136-44.
7. Schuman JS. Antiglaucoma medications: A review of safety and tolerability issues related to their use. Clin Ther 2000; 22: 167-208.
8. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996; 103: 1661-9.
9. Rochtchina E, Mitchell P. Projected number of Australians with glaucoma in 2000 and 2030. Clin Experiment Ophthalmol 2000; 28: 146-8.
10. Mukesh BN, McCarty CA, Rait JL, Taylor HR. Five-year incidence of open-angle glaucoma: The visual impairment project. Ophthalmology 2002; 109: 1047-51.
11. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005; 112: 863-8.
12. South East Asia Glaucoma Interest Group. Asia Pacific Glaucoma Guidelines, 2003-2004. Accessed October 2005. Available at: http://www.seagig.org/apgg.php
13. Schuman JS. Effects of systemic β blocker therapy on the efficacy and safety of topical brimonidine and timolol. Ophthalmology 2000; 107: 1171-7.
14. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-97.
15. Robertson J, Fryer JL, O'Connell DL et al. Limitations of Health Insurance Commission (HIC) data for deriving prescribing indicators. Med J Aust 2002; 176: 419-24.
16. Nelson MR, Tonkin AM, Cicuttini FM et al. COX-2 inhibitors: Exemplars of the drug-safety conundrum. Med J Aust 2005; 182: 262-3.
17. Centrelink. A Guide to Centrelink Concession Cards. Accessed November 2005. Available at: Http://www.centrelink.gov.au/internet/internet.nsf/ publications/co153.htm
18. Sayer GP, McGeechan K, Kemp A et al. The General Practice Research Network: The capabilities of an electronic patient management system for longitudinal patient data. Pharmacoepidemiol Drug Saf 2003; 12: 483-9.
19. Francis B, Green M, Payne C. The GLIM System: Generalised Linear Interactive Modelling. Oxford: Oxford University Press, 1993.
20. Batchelor ED, O'Day DM, Shand DG et al. Interaction of topical and oral timolol in glaucoma. Ophthalmology 1979; 86: 60-5.
21. Blondeau P, Côté M, Tétrault L. Effect of timolol eye drops in subjects receiving systemic propranolol therapy. Can J Ophthalmol 1983; 18: 18-21.
22. NSW Medicines Information Centre. Co-prescription of Topical and Systemic β-Blockers. 2005. Available at: http://www.clininfo.health.nsw.gov.au/specialties/MIC/.
23. Merck Sharp & Dohme. Australian Product Information for TIMOPTOL XE ® (Timolol Maleate). 2005. Accessed October 2005. Available at: http://www.msd4gps.com.au/msdforgps/productinfo.do?prod=timoptol_xe
24. Chua B, Rochtchina E, Mitchell P. Temporal changes in the control of blood pressure in an older Australian population. J Hum Hypertens 2005; 19: 691-6.
25. IMS Health. Moving Annual Total Sales Data for Systemic Beta-Blockers; 1997-2004.
26. Gottfredsdottir MS, Allingham RR, Shields MB. Physicians' guide to interactions between glaucoma and systemic medications. J Glaucoma 1997; 6: 377-83.
27. Australian Bureau of Statistics. Population Size and Growth. Year Book Australia, 2005. Accessed October 2005. Available at: http://www.abs.gov.au/ausstats/abs@.nsf/ 94713ad445ff1425ca25682000192af2/6a5aabd7621230adca256f7200832f77! OpenDocument
28. Vuori ML, Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol 1995; 233: 131-4.
29. Frishman WH, Kowalski M, Nagnur S et al. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: Focus on beta-adrenergic blockade. Heart Dis 2001; 3: 386-97.
30. Cox A. Systemic effects of ocular drugs. Adverse Drug React Bull 2002; 215: 823-6.
31. Fraunfelder FT, Meyer SM. Systemic reactions to ophthalmic drug preparations. Med Toxicol Adverse Drug Exp 1987; 2: 287-93.
32. Jampel HD, Parekh P, Johnson E, Miller R. Chart documentation by general physicians of the glaucoma medications taken by their patients. Am J Ophthalmol 2005; 140: 344-5.
33. Kerr SJ, Mant A, Horn FE et al. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust 2003; 179: 403-7.
34. Wood L, Martinez C. The general practice research database: Role in pharmacovigilance. Drug Saf 2004; 27: 871-81.
35. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 2004; 137 (Suppl.): S13-16.